Back to Search Start Over

Seroprevalence of seven high-risk HPV types in The Netherlands.

Authors :
Scherpenisse M
Mollers M
Schepp RM
Boot HJ
de Melker HE
Meijer CJ
Berbers GA
van der Klis FR
Source :
Vaccine [Vaccine] 2012 Oct 19; Vol. 30 (47), pp. 6686-93. Date of Electronic Publication: 2012 Sep 07.
Publication Year :
2012

Abstract

Background: To obtain insight into the age-specific seroprevalence for seven high-risk human papillomavirus (hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) among the general population in the pre-vaccination era in The Netherlands.<br />Methods: From a cross-sectional population-based study (ISRCTN 20164309) performed in 2006/2007 6384 sera of men, women and children were tested for seven hr-HPV specific antibodies using a fluorescent bead-based multiplex immunoassay with virus-like particles of the seven HPV serotypes.<br />Results: An increase in seroprevalence was observed in adolescents, especially for the most prevalent HPV type 16 (up to 11.3%). The increase was most pronounced in women, but was less clear for the other six HPV serotypes. Relatively stable seroprevalences were found in the middle aged cohorts and a slight decrease in the elderly. For the age cohorts >14 years, the seroprevalence among women (25.2%) was higher compared with men (20.3%) (p=0.0002). We found that 10.1% of the population was seropositive for multiple HPV serotypes.<br />Conclusions: The HPV vaccination program is targeted at preadolescents as is justified by the results in this study in which a step-up in HPV seroprevalence is observed at ages of sexual debut. Although direct interpretation of seroprevalence data are hampered by cross-reactivity and seroconversion rate, these data are useful as baseline to evaluate long-term population effects of the HPV16/18 vaccination program.<br /> (Copyright © 2012 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1873-2518
Volume :
30
Issue :
47
Database :
MEDLINE
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
22959981
Full Text :
https://doi.org/10.1016/j.vaccine.2012.08.068